IGF1R and breast carcinoma: The first assessment of IGF-1R targeted treatment used αIR-3, a mouse monoclonal antibody (mAb), which blocked IGF-1 binding to IGF-1R and inhibited growth of estrogen-independent breast cancers in vitro and in vivo (4–6).